Podcast
MSL Talk: Tom Caravela, Ike Ogbaa
How to leverage KOL relationships to achieve strategic objectives with Dr. Aoife O'Dwyer
Summary
My guest today is Aoife O Dwyer, Founder of MSL Consultant, and we discuss how to leverage KOL relationships to achieve strategic objectives.
In this episode:
- What made Aoife decide to become an MSL Consultant and what she likes best about her role
- Aoife’s advice to MSLs who want to demonstrate their value to their company
- Most important things for people to remember in KOL identifications and stakeholder mapping
- Tips on getting a KOL meeting
- How can an MSL deliver value in a KOL meeting
- How can an MSL plan for a KOL meeting
- How has COVID affected an MSL’s ability to provide value and what advice Aoife can give to MSLs in handling this crisis
- What skills are now mandatory for MSLs during and after the COVID crisis to provide value to their KOLs and to their organization
- How Aoife expects Pharma to change practices as a result of Covid-19
- Advice to MSLs to help aid in their success
MSL Consultant, KOL relationships, strategic objectives, stakeholder mapping, Pharma practices
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Ike Ogbaa
Podcast
MSL Talk: Tom Caravela, Bernadett Mamone
What I DO….How I BUILD Relationships
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary